Daily Medication Pearl: Cabenuva (Cabotegravir-rilpivirine)

Medication Pearl of the Day: Cabenuva (Cabotegravir-rilpivirine)

Indication: Cabenuva (Cabotegravir-rilpivirine) is a 2-drug co-packaged product of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), which is indicated as a complete regimen for the treatment of HIV-1 infection in adults.

Insight:

• Dosing: The recommended dosing schedule is an initiation of injections of Cabenuva (Cabotegravir-rilpivirine) at 600 mg of cabotegravir and 900 mg of rilpivirine on the last day of oral lead-in and continue with injections of Cabenuva (Cabotegravir-rilpivirine) (400 mg of cabotegravir and 600 mg of rilpivirine) every month thereafter.
• Dosage forms: Cabenuva (Cabotegravir-rilpivirine) comes in 2 dosage forms: the 400-mg/600-mg kit, containing a single-dose vial of 400 mg/2 ml and a single-dose vial of 600 mg/2 mL (300 mg/mL); and the 600-mg/900-mg kit, containing a single-dose vial of 600 mg/3 mL and a single-dose vial of 900 mg/3 mL (300 mg/mL).
• Adverse events (AEs): The most common AEs were injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash.
• Mechanism of action: Cabenuva (Cabotegravir-rilpivirine)contains 2 long-acting HIV-1 antiretroviral drugs, cabotegravir, and rilpivirine.
• Manufacturer: ViiV healthcare

Source:

1. US Product Labeling @std Template for PLR (gskpro.com)
2. Once-a-Month HIV Treatment | CABENUVA (cabotegravir; rilpivirine)